1
|
Shafiekhani M, Fatemi SA, Hosseini P, Marhemati F, Mohammadi S, Sharifi F, Moorkani Kurde Esfahani Pour A, Sadeghi Habibabad F, Saad Abadi N, Shorafa E, Azadi S. Pharmacokinetic and Pharmacodynamic Considerations of Novel Antibiotic Agents for Pediatric Infections: A Narrative Review. Surg Infect (Larchmt) 2023; 24:703-715. [PMID: 37831932 DOI: 10.1089/sur.2023.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2023] Open
Abstract
Background: Currently, the escalation of microbial resistance poses a significant global challenge. Children are more susceptible to develop infections and therefore are prescribed antibiotics more frequently. The overuse and misuse of antibiotics in pediatric patients can play a considerable role in developing microbial resistance. Accordingly, many policies, including research into new antibiotic agents have been recommended to combat microbial resistance. Recent developments in novel antibiotics have shown promising results against multi-drug resistant (MDR) and extensive drug resistance (XDR) pathogens. However, as pediatric patients are typically excluded from the clinical trials of new medications, labeling and information about approved antibiotics should be improved. This study aimed to evaluate antibiotics having been introduced to the market in the last decade focusing on pediatric population. Methods: This study reviewed the published literatures on novel FDA-approved antibiotics released between 2010 and 2022. Results: Finally, seven newly approved antibiotics including ceftaroline fosamil, ceftazidime-avibactam, ceftolozane-tazobactam, ceftobiprole, imipenem-cilastatin-relebactam, meropenem-vaborbactam, and tedizolid were considered in the present review-article. All relevant data extracted from literatures, were discussed in different subtitles of "Pharmacology", "Mechanism of action", "Indication", "Dosage regimen and pharmacokinetic and pharmacodynamic properties", "Dosage adjustment in renal/liver failure", "Resistance pattern", and "Adverse drug events". Conclusion: This study reviewed available data on seven new antibiotic agents and their pharmacodynamic and pharmacokinetic properties, with a particular focus on their use in pediatric patients. The information presented in this review will be useful for healthcare professionals in selecting appropriate antibiotics for pediatric patients and for researchers in achieving the ideal therapeutic regimens.
Collapse
Affiliation(s)
- Mojtaba Shafiekhani
- Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
- Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
- Shiraz Transplant Center, Abu-Ali Sina Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
| | | | - Pouria Hosseini
- Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Fatemeh Marhemati
- Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Soniya Mohammadi
- Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Fatemeh Sharifi
- Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
| | | | | | - Negin Saad Abadi
- Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Eslam Shorafa
- Department of Pediatrics, Division of Pediatric Intensive Care, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Soha Azadi
- Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
- Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
| |
Collapse
|
2
|
Bologna M, Blasi MA, Carlucci G, Biordi L, Biordi N, Balestrazzi E. Imipenem Reaches Therapeutic Concentrations in Aqueous Humor, as Determined by Hplc. Eur J Ophthalmol 2018; 3:26-30. [PMID: 8485395 DOI: 10.1177/112067219300300105] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The majority of ocular infections in the industrialized countries arise after surgical interventions. An appropriate antibacterial prophylaxis is therefore highly desirable in eye surgery. We used high performance liquid chromatography (HPLC) to measure the concentrations reached by imipenem, a modern wide-spectrum beta-lactam antibiotic, in plasma and aqueous humor of 26 patients scheduled for cataract surgery. Even a single 500 mg dose of imipenem achieved therapeutic levels of the molecule for the most common ophthalmic pathogens (1μg/ml or above) in the aqueous humor within one to two hours after administration. This drug may therefore be suitable for antibacterial prophylaxis in eye surgery.
Collapse
Affiliation(s)
- M Bologna
- Department of Experimental Medicine, University of L'Aquila, Italy
| | | | | | | | | | | |
Collapse
|
3
|
Abstract
Imipenem/cilastatin is the first of a new class of β-lactam antibiotics called carbapenems. The antibacterial spectrum of imipenem exceeds any antibiotic investigated to date and includes gram-positive, gram-negative, and anaerobic organisms. Only methicillin-resistant organisms, Strep. faecium, Pseudomonas cepacia, and Pseudomonas maltophilia have been shown to be resistant. Imipenem is administered in a 1:1 ratio with cilastatin, which inhibits a renal enzyme (dehydropeptidase) and improves urinary recovery of imipenem. The elimination half-life of both compounds is 1.0 hours and recommended doses are 0.25–0.5 g iv q6h. Adverse events are similar in nature and incidence to β-lactam antibiotics, with phlebitis/thrombophlebitis, diarrhea, nausea, skin rash, and elevations of hepatic enzymes most common. Clinical studies in phase II and III trials have shown imipenem/cilastatin to be effective in soft tissue infections, endocarditis, obstetrics and gynecology, complicated urinary tract infections, mixed anaerobic-aerobic infections, osteomyelitis, bacteremias, and pneumonias. Several comparative clinical trials have shown imipenem/cilastatin to be equal in efficacy to combination therapy. Imipenem/cilastatin may prove to be an alternative to combination antibiotic therapy because of its extremely broad spectrum of activity.
Collapse
Affiliation(s)
| | - James A. Lyon
- Clinical Pharmacy, Duquesne University School of Pharmacy, Pittsburgh, PA 15213; and Special Projects, PharmaKinetics, Inc., Baltimore, MD
| |
Collapse
|
4
|
Abstract
The threat of antibacterial resistance continues to increase globally, and therapeutic options for the treatment of some serious infectious diseases are diminishing. The carbapenems are a potent class of broad-spectrum drugs, and their stability against hydrolysis by many important beta-lactamases make them an important weapon in the treatment of beta-lactamase-producing bacterial pathogens. This review focuses on four carbapenems of clinical importance in the USA: imipenem, meropenem, ertapenem and doripenem. After a historical review of carbapenem development, these four carbapenems are evaluated based on their mechanism of action, spectrum of activity, potency, pharmacodynamics, clinical pharmacokinetics, clinical profiles and toxicity issues.
Collapse
Affiliation(s)
- Philip D Lister
- Creighton University School of Medicine, Department of Medical Microbiology and Immunology, 2500 California Plaza, Omaha, NE 68178, USA.
| |
Collapse
|
5
|
Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. Can J Infect Dis 2012; 9:215-28. [PMID: 22346545 DOI: 10.1155/1998/831425] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/1997] [Accepted: 11/11/1997] [Indexed: 11/17/2022] Open
Abstract
OBJECTIVE To compare and contrast imipenem and meropenem in terms of in vitro activity, pharmacokinetics, clinical efficacy and adverse effects. DATA SELECTION MEDLINE search from 1975 to 1997 and follow-up of references. DATA EXTRACTION Clinical trials comparing imipenem with meropenem, or either imipenem or meropenem with standard therapy in the treatment of serious infections were selected. DATA SYNTHESIS Imipenem, the first carbapenem, was first marketed in 1987; meropenem was introduced to the market in 1996. In general, imipenem is more active against Gram-positive cocci while meropenem is more active against Gram-negative bacilli. The agents display similar pharmacokinetics. Clinical studies in patients with serious infections (intra-abdominal infection, respiratory infection, septicemia, febrile neutropenia) report similar bacteriological and clinical cure rates with imipenem and meropenem. Meropenem is approved for the treatment of bacterial meningitis, whereas imipenem is not. Adverse effects are similar. CONCLUSIONS Current literature supports the use of imipenem at a dose of 500 mg every 6 h and meropenem at 1 g every 8 h for the treatment of severe infections. For the treatment of serious infections, imipenem (500 mg every 6 h or 2 g/day [$98/day]) is more economical than meropenem (1 g every 8 h or 3 g/day [$142/day]) based on acquisition cost.
Collapse
|
6
|
Kioumis IP, Kuti JL, Nicolau DP. Intra-abdominal infections: considerations for the use of the carbapenems. Expert Opin Pharmacother 2007; 8:167-82. [PMID: 17257087 DOI: 10.1517/14656566.8.2.167] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Intra-abdominal infection remains a common and frequently severe medical condition, carrying with it significant morbidity and mortality. These infections are almost always polymicrobial in nature as they are caused by mixed aerobic/anaerobic intestinal flora. Despite substantial improvements in both the medical and surgical management of these infections over the last several decades, there remains an opportunity to further enhance the utilization of adjunctive antibiotic therapy. As a result of the epidemiology and the current resistance profile of the infecting pathogens, the carbapenems represent a class of antibiotics that are considered appropriate for the treatment of severe intra-abdominal infections. This review will discuss the classification and microbiology of these infections and emerging resistance in the pathogens of interest. The review also and focuses on the role of the carbapenems in the management of the constellation of diseases known as intra-abdominal infection.
Collapse
Affiliation(s)
- Ioannis P Kioumis
- Center for Anti-infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA
| | | | | |
Collapse
|
7
|
Bouza E, Burillo A, Muñoz P. Antimicrobial therapy of Clostridium difficile-associated diarrhea. Med Clin North Am 2006; 90:1141-63. [PMID: 17116441 DOI: 10.1016/j.mcna.2006.07.011] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Clostridium difficile-associated diarrhea (CDAD) is the most common etiologically-defined cause of hospital-acquired diarrhea. Caused by the toxins of certain strains of C difficile, CDAD represents a growing concern, with epidemic outbreaks in some hospitals where very aggressive and difficult-to-treat strains have recently been found. Incidence of CDAD varies ordinarily between 1 to 10 in every 1,000 admissions. Evidence shows that CDAD increases morbidity, length of stay, and costs. This article described the clinical manifestations of CDAD, related risk factors, considerations for confirming CDAD, antimicrobial and non-antimicrobial treatment of CDAD, and issues related to relapses. The article concludes with a discussion of recent epidemic outbreaks involving CDAD.
Collapse
Affiliation(s)
- Emilio Bouza
- Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Dr. Esquerdo 46, 28007 Madrid, Spain
| | | | | |
Collapse
|
8
|
Jamal WY, Mokaddas EM, Verghese TL, Rotimi VO. In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait. Int J Antimicrob Agents 2002; 20:270-4. [PMID: 12385683 DOI: 10.1016/s0924-8579(02)00180-2] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
A total of 73 clinical isolates of Clostridium difficile isolated from stool/rectal swabs of patients admitted to the intensive care units at Mubarak Hospital, Ibn Sina Hospital Burn unit and Haematology wards at the Kuwait Cancer Control Centre, were investigated for their susceptibility to 15 antibiotics using the Etest. Amoxycillin-clavulanic acid, ampicillin, meropenem, metronidazole, penicillin, piperacillin, piperacillin/tazobactam, teicoplanin and vancomycin had excellent activities with MIC(90)s of 0.38, 0.5, 1, 0.19, 1.5, 2, 3, 0.25 and 0.75 mg/l, respectively. Of the 73 C. difficile isolates, 86% were resistant to imipenem (MIC(90) >32 mg/l) and almost 97% were resistant to trovafloxacin (MIC(90)>256 mg/l). Forty eight percent of the isolates were resistant to clindamycin. A total of 18 isolates were highly clindamycin-resistant with an MIC of >256 mg/l; 10 of these were toxin producers. Multiple antibiotic resistance (two or more antibiotics) was noted in 63 isolates. These were more common among the toxigenic strains than the non-toxigenic strains by a ratio of 2.5:1.
Collapse
Affiliation(s)
- Wafaa Y Jamal
- Department of Microbiology, Faculty of Medicine, Kuwait University and Mubarak Al-Kabeer Teaching Hospital, P.O. Box 24923, 13110, Safat, Kuwait
| | | | | | | |
Collapse
|
9
|
Affiliation(s)
- Patrick Duff
- Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of Florida, College of Medicine, Gainesville, Florida 32610-0294, USA.
| |
Collapse
|
10
|
Jones RN. Prediction of enterococcal imipenem susceptibility using ampicillin or penicillin MICs: more evidence for a class concept. J Clin Microbiol 2001; 39:3810-1. [PMID: 11599520 PMCID: PMC88444 DOI: 10.1128/jcm.39.10.3810-3811.2001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Abstract
Understanding the breadth of systemic antimicrobial agents available for use by the dermatologist and their associated side-effect profiles and drug interactions allows the clinician to offer patients optimal care in the management of cutaneous infectious disease.
Collapse
Affiliation(s)
- N S Sadick
- Department of Dermatology, Weill Medical College of Cornell University, New York City, New York, USA
| |
Collapse
|
12
|
Novelli A, Fallani S, Cassetta MI, Conti S, Mazzei T. Postantibiotic leukocyte enhancement of meropenem against gram-positive and gram-negative strains. Antimicrob Agents Chemother 2000; 44:3174-6. [PMID: 11036045 PMCID: PMC101625 DOI: 10.1128/aac.44.11.3174-3176.2000] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The postantibiotic leukocyte enhancement (PALE) of meropenem in vitro in comparison with that of imipenem was evaluated with 24 recently isolated gram-positive and gram-negative strains. In general, pre-exposure to carbapenems (at four times the MIC for 2 h) led to increased polymorphonuclear cell phagocytic killing. The PALE of imipenem was generally significantly less than that observed with meropenem.
Collapse
Affiliation(s)
- A Novelli
- Dipartimento di Farmacologia Preclinica e Clinica, Università degli Studi di Firenze, Florence, Italy.
| | | | | | | | | |
Collapse
|
13
|
Diekema DJ, Coffman SL, Marshall SA, Beach ML, Rolston KV, Jones RN. Comparison of activities of broad-spectrum beta-lactam compounds against 1,128 gram-positive cocci recently isolated in cancer treatment centers. Antimicrob Agents Chemother 1999; 43:940-3. [PMID: 10103204 PMCID: PMC89230 DOI: 10.1128/aac.43.4.940] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
We report the in vitro activities of broad-spectrum beta-lactam antimicrobials tested against 1,128 gram-positive pathogens recently isolated from cancer patients. Cefepime and imipenem were more active than ceftazidime and ceftriaxone against these organisms. Only vancomycin demonstrated reliable activity against oxacillin-resistant staphylococci, Enterococcus spp., and Corynebacterium spp. The spectrum of gram-positive organisms against which cefepime and imipenem have activity provides an advantage over ceftazidime as empiric therapy for cancer patients, potentially reducing the need for the empiric addition of glycopeptides.
Collapse
Affiliation(s)
- D J Diekema
- Department of Pathology, University of Iowa College of Medicine, Iowa City 52242, USA.
| | | | | | | | | | | |
Collapse
|
14
|
Allo MD, Bennion RS, Kathir K, Thompson JE, Lentz M, Meute M, Finegold SM. Ticarcillin/Clavulanate versus Imipenem/Cilistatin for the Treatment of Infections Associated with Gangrenous and Perforated Appendicitis. Am Surg 1999. [DOI: 10.1177/000313489906500201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The objective of this study was to compare ticarcillin/clavulanate given at 3.1 g every 6 hours with imipenem/cilistatin given at 500 mg every 6 hours for the treatment of infections associated with gangrenous or perforated appendicitis. One hundred thirty-seven patients were found to have gangrenous or perforated appendicitis and received the study medication for 3 to 5 days in a double-blinded, randomized manner. Clinical success was similar for the two treatment groups, 96.9 and 95.9 per cent in the ticarcillin/clavulanate and imipenem/cilistatin groups, respectively (P = 0.99; 95% confidence interval for the difference was -5.6% to 7.6%). Bacteriologic success at the end of therapy was similar in the two groups, 100 and 98.4 per cent in the ticarcillin/clavulanate and imipenem/cilistatin groups, respectively (P = 0.99; 95% confidence interval for the difference was -1.8% to 4.7%). The occurrence of adverse events related to treatment was similar for the two groups (P = 0.31) and led to study withdrawal for four patients (one with ticarcillin/clavulanate and three with imipenem/cilistatin). Ticarcillin/clavulanate given at 3.1 g every 6 hours is as effective and as safe as imipenem/cilistatin given at 500 mg every 6 hours for treatment of gangrenous or perforated appendicitis.
Collapse
Affiliation(s)
- Maria D. Allo
- Department of Surgery, Santa Clara Valley Medical Center, San Jose
| | - Robert S. Bennion
- Departments of Medicine and Surgery, University of California at Los Angeles, Los Angeles
- Olive View Medical Center, Sylmar, California
| | - Krishna Kathir
- Department of Surgery, Santa Clara Valley Medical Center, San Jose
| | - Jesse E. Thompson
- Departments of Medicine and Surgery, University of California at Los Angeles, Los Angeles
| | - Melinda Lentz
- Department of Surgery, Santa Clara Valley Medical Center, San Jose
| | - Margaret Meute
- Department of Surgery, Santa Clara Valley Medical Center, San Jose
| | - Sydney M. Finegold
- Departments of Medicine and Surgery, University of California at Los Angeles, Los Angeles
| |
Collapse
|
15
|
Epstein ME, Amodio-Groton M, Sadick NS. Antimicrobial agents for the dermatologist. I. Beta-lactam antibiotics and related compounds. J Am Acad Dermatol 1997; 37:149-65; quiz 166-8. [PMID: 9270499 DOI: 10.1016/s0190-9622(97)80118-1] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We review the newer antimicrobial agents that are being employed by dermatologists with increased frequency as well as some of the more commonly used older agents. Particular emphasis is based on selection factors such as causative pathogens and their resistance profiles, routes of administration, toxicity, drug interactions, and dosing requirements. Emphasis in this review is on the newer classes of antimicrobials such as third- and fourth-generation cephalosporins; beta-lactam, beta-lactamase inhibitor combination agents; monobactams; carbapenems; macrolides; and fluoroquinolones. Dermatologic indications and treatment alternatives are highlighted; this will expand the practicing clinician's therapeutic armamentarium and enable him/her to make rational decisions concerning treatment approaches to infectious disease problems encountered in daily practice.
Collapse
Affiliation(s)
- M E Epstein
- Department of Medicine, North Shore University Hospital, Manhasset, New York, USA
| | | | | |
Collapse
|
16
|
Abstract
Penicillin and ampicillin are valuable antibiotics in obstetrics because of their excellent activity against group A and group B streptococci. In addition, ampicillin is the treatment of choice for enterococcal infections, particularly urinary tract infections. Limited spectrum cephalosporins are of primary value as prophylactic agents. Ceftriaxone, an intermediate spectrum agent, is an excellent drug for treatment of infections caused by N. gonorrhoeae. Extended spectrum cephalosporins, penicillins, and carbapenems provide sufficient coverage against pathogenic organisms to be used as single agents for treatment of polymicrobial infections such as chorioamnionitis and puerperal endometritis. Alternatively, combination regimens such as clindamycin or metronidazole plus an aminoglycoside or aztreonam are also highly effective in this clinical situation. Erythromycin and azithromycin have value primarily for treatment of endocervical chlamydial infections and mycoplasma pneumonia in obstetric patients and for intrapartum prophylaxis against group B streptococcal infection in patients who are allergic to beta-lactam antibiotics.
Collapse
Affiliation(s)
- P Duff
- Division of Maternal-Fetal Medicine, University of Florida College of Medicine, Gainesville, USA
| |
Collapse
|
17
|
Zerva L, Biedenbach DJ, Jones RN. Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks. J Clin Microbiol 1996; 34:1970-4. [PMID: 8818892 PMCID: PMC229164 DOI: 10.1128/jcm.34.8.1970-1974.1996] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
A collection of 300 Haemophilus influenzae clinical strains was used to assess in vitro susceptibility to carbapenems (meropenem, imipenem) by MIC and disk diffusion methods and to compare disk diffusion test results with two potencies of ampicillin disks (2 and 10 micrograms). The isolates included ampicillin-susceptible or- intermediate (167 strains), beta-lactamase-positive (117 strains), and beta-lactamase-negative ampicillin-resistant (BLNAR; 16 strains) organisms. Disk diffusion testing was performed with 10-micrograms meropenem disks from two manufacturers. Meropenem was highly active against H. influenzae strains (MIC50, 0.06 microgram/ml; MIC90, 0.25 microgram/ml; MIC50 and MIC90, MICs at which 50 and 90%, respectively, of strains are inhibited) and was 8- to 16-fold more potent than imipenem (MIC50, 1 microgram/ml; MIC90, 2 micrograms/ml). Five non-imipenem-susceptible strains were identified (MIC, 8 micrograms/ml), but the disk diffusion test indicated susceptibility (zone diameters, 18 to 21 mm). MIC values of meropenem, doxycycline, ceftazidime, and ceftriaxone for BLNAR strains were two- to fourfold greater than those for other strains. The performance of both meropenem disks was comparable and considered acceptable. A single susceptible interpretive zone diameter of > or = 17 mm (MIC, < = or 4 micrograms/ml) was proposed for meropenem. Testing with the 2-micrograms ampicillin disk was preferred because of an excellent correlation between MIC values and zone diameters (r = 0.94) and superior interpretive accuracy with the susceptible criteria at > or = 17 mm (MIC, < or = 1 microgram/ml) and the resistant criteria at < or = 13 mm (MIC, > or = 4 micrograms/ml). Among the BLNAR strains tested, 81.3% were miscategorized as susceptible or intermediate when the 10-micrograms ampicillin disk was used, while the 2-micrograms disk produced only minor interpretive errors (12.5%). Use of these criteria for testing H. influenzae against meropenem and ampicillin should maximize reference test and standardized disk diffusion test performance with the Haemophilus Test Medium. The imipenem disk diffusion test appears compromised and should be used with caution for detecting strains for which imipenem MICs are elevated.
Collapse
Affiliation(s)
- L Zerva
- Department of Pathology, University of Iowa College of Medicine, Iowa City 52242, USA
| | | | | |
Collapse
|
18
|
Jones RN. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med 1996; 100:3S-12S. [PMID: 8678095 DOI: 10.1016/s0002-9343(96)00102-7] [Citation(s) in RCA: 105] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The selection of drug-resistant pathogens in hospitalized patients with serious infections such as pneumonia, urinary tract infections (UTI), skin and skin-structure infections, and primary or secondary bacteremia has generally been ascribed to the widespread use of antimicrobial agents. Issues of concern regarding gram-negative bacilli include the expression of extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumonias and constitutive resistance in some Enterobacteriaceae caused by Bush group 1 beta-lactamases. Current concerns with gram-positive pathogens are increasing multidrug resistance in methicillin-resistant Staphylococcus aureus, enterococci, and coagulase-negative staphylococci, and increasing incidence of penicillin-resistant Streptococcus pneumoniae. Contemporary treatment strategies for pneumonia in hospitalized patients mandate early empiric therapy for the most likely gram-positive and gram-negative pathogens. Newer beta-lactams, such as fourth-generation cephalosporins, may be useful in the treatment of pneumonia, including those cases associated with bacteremia. Combination beta-lactam/beta-lactamase inhibitor drugs, an aminoglycoside co-drug, or a carbapenem may also be indicated. The initial treatment of UTI in the hospital setting also may be empirically treated with the newer cephalosporins, combination broad-spectrum penicillins plus an aminoglycoside, a quinolone, or a carbapenem. Current problems in treating UTI include the emergence of extended spectrum beta-lactamase-producing Escherichia coli, the tendency of fluoroquinolones both to select for resistant strains of major UTI pathogens and to induce cross-resistance among different drug classes, and beta-lactam and vancomycin resistance of enterococci and coagulase-negative staphylococci. Treatment of skin and skin-structure infections is complicated by the coexistence of gram-positive and gram-negative infections, which may be drug resistant. Both fourth-generation beta-lactams and carbapenems may have in vitro activity against these pathogens; however, where these drugs--with their increased spectra and lower affinity for beta-lactamases and less susceptibility to beta-lactamase hydrolysis--fit into the therapeutic armamentarium remains to be determined. Initial clinical studies appear to be promising, nonetheless. The ability of both nosocomial and community-acquired pathogens to develop resistance to powerful broad-spectrum agents presents a great challenge for prescribing patterns and in the development of new drugs to be relatively resistant to inactivation.
Collapse
Affiliation(s)
- R N Jones
- Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA
| |
Collapse
|
19
|
Angerås MH, Darle N, Hamnström K, Ekelund M, Engström L, Takala J, Viste A, Holme JB. A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 1996; 28:513-8. [PMID: 8953684 DOI: 10.3109/00365549609037950] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
515 patients with intra-abdominal infection participated in an open randomized comparative multicenter trial in order to compare the efficacy, safety, and tolerance of imipenem/cilastatin with cefuroxime/metronidazole. 258 patients (mean age 56 years) received imipenem/cilastatin 1.5-2.0 g/day, and 257 patients (mean age 54 years) received cefuroxime 3.0-4.5 g/day plus metronidazole 1.0-1.5 g/day for at least 3 days. 130/161 evaluable patients (80.8%) receiving imipenem/cilastatin and 124/145 evaluable patients (85.5%) receiving cefuroxime/metronidazole were clinically cured. The microbiological response was favorable in 86.9% in the imipenem/cilastatin group and in 90.8% in the cefuroxime/metronidazole group. The two treatment groups were similar with respect to median time to defervescence which was 4 days. The median duration of treatment was 6 days and the median time to discharge from hospital was 9 days in both groups. Drug-related adverse reactions were observed in 14 patients receiving iminpenem/cilastatin and in 8 patients receiving cefuroxime/metronidazole. 19 patients in the imipenen/cilastatin group and 12 patients in the cefuroxime/metronidazole group died. No correlation was found between the deaths and the study drugs. The present study shows that intra-abdominal infections can be treated successfully with imipenem/cilastatin as well as with cefuroxime/metronidazole.
Collapse
Affiliation(s)
- M H Angerås
- Department of Surgery, Ostra Hospital, University of Göteborg, Sweden
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Fujita J, Yamadori I, Xu G, Hojo S, Negayama K, Miyawaki H, Yamaji Y, Takahara J. Clinical features of Stenotrophomonas maltophilia pneumonia in immunocompromised patients. Respir Med 1996; 90:35-8. [PMID: 8857324 DOI: 10.1016/s0954-6111(96)90242-5] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Between January 1988 and December 1992, 68 patients admitted to our Department of Internal Medicine with haematological malignancies or solid tumours showed colonization of the respiratory tract with Stenotrophomonas maltophilia. To characterize the significance of respiratory tract colonization by S. maltophilia, we retrospectively reviewed the medical records of the 68 patients colonized with this organism. Twenty-nine of these 68 patients developed pneumonia, with S. maltophilia being implicated in 10 cases. The majority of these 10 patients showed lobular infiltration on chest X-ray. Pleural effusion was observed in two (20%) of the 10 patients. All 68 strains of S. maltophilia were resistant to imipenem. Latamoxef was effective against 98 center dot 5% of strains, while minocycline was effective against 100% of strains. This report describes the clinical features of nosocomial S. maltophilia pneumonia in immunocompromised patients.
Collapse
Affiliation(s)
- J Fujita
- First Department of Internal Medicine, Kagawa Medical School, Japan
| | | | | | | | | | | | | | | |
Collapse
|
21
|
|
22
|
Etiology of nosocomial infections and the susceptibility of nosocomial pathogens to imipenem and other antimicrobial agents at a tertiary care referral hospital. Curr Ther Res Clin Exp 1995. [DOI: 10.1016/0011-393x(95)85058-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Abstract
When treating any infectious disease, a physician selects an antimicrobial based on the following considerations: the in vitro activity of the drug, its pharmacokinetic properties, the efficacy data based on properly designed and conducted clinical trials, and finally the adverse effects. In this article, all of these factors, with the exception of adverse effects, were discussed. It was neither my intent nor my purpose to deal with side effects or adverse drug reactions because these are well covered in standard texts or physician references such as the Physicians' Desk Reference and the American Hospital Formulary Service (United States) and the Compendium of Pharmaceuticals and Specialties (Canada).
Collapse
Affiliation(s)
- L A Mandell
- Division of Infectious Diseases, McMaster University, Hamilton, Ontario, Canada
| |
Collapse
|
24
|
Cooper GL, Louie A, Baltch AL, Chu RC, Smith RP, Ritz WJ, Michelsen P. Influence of zinc on Pseudomonas aeruginosa susceptibilities to imipenem. J Clin Microbiol 1993; 31:2366-70. [PMID: 8408557 PMCID: PMC265762 DOI: 10.1128/jcm.31.9.2366-2370.1993] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
Serial dilution susceptibility testing of imipenem against 59 clinical isolates of Pseudomonas aeruginosa, conducted simultaneously on single lots of Difco and BBL Mueller-Hinton agar (MHA), resulted in MICs for 90% of strains tested of 8 and 16 micrograms/ml, respectively. MICs for Escherichia coli, Klebsiella pneumoniae, and Pseudomonas spp. were also higher on BBL MHA. Quantification of the cation content of the two MHAs by atomic absorption spectroscopy demonstrated that the zinc concentration in BBL MHA was 15 times greater than that measured in Difco MHA (2.61 and 0.17 micrograms/ml, respectively). Concentrations of calcium, magnesium, iron, manganese, and copper in the two agars were similar. Addition of zinc to Difco MHA resulted in increases in MICs of imipenem for P. aeruginosa but not in the MICs of ceftazidime or cefpirome for P. aeruginosa (P < 0.01). A lesser zinc effect was seen on the activity of imipenem against E. coli, K. pneumoniae, and Pseudomonas spp. The activities of ceftazidime and cefpirome were similar on both MHAs when tested against all gram-negative organisms in this study. Thus, the effect of zinc in MHA was clearly demonstrated by a significant increase in the MICs of imipenem for P. aeruginosa, and, to a lesser extent, for other gram-negative bacilli.
Collapse
Affiliation(s)
- G L Cooper
- Department of Medicine, Stratton VA Medical Center, Albany, New York 12208
| | | | | | | | | | | | | |
Collapse
|
25
|
Sader HS, Jones RN. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs. Eur J Clin Microbiol Infect Dis 1993; 12:384-91. [PMID: 8354307 DOI: 10.1007/bf01964439] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
The in vitro activity of biapenem was compared to that of imipenem, meropenem and other broad-spectrum beta-lactams. A total of 716 isolates from recent cases of clinical septicemia and an additional 137 stock strains possessing known beta-lactamases or other well-characterized resistance mechanisms were tested. The minimal concentrations inhibiting 90% of strains (MIC90) of Enterobacteriaceae species were for biapenem 0.03 to 1 mg/l and for imipenem 0.25 to 2 mg/l. No member of the Enterobacteriaceae was found to be resistant to biapenem. Biapenem and meropenem were the most active drugs against Pseudomonas aeruginosa, with an MIC90 of 1 mg/l. Biapenem was more active than ceftazidime against most gram-negative and gram-positive bacteria tested. Biapenem was as potent as imipenem against anaerobic bacteria (including Bacteroides fragilis), with an MIC90 of 0.25 mg/l. High MICs of biapenem were demonstrated for Xanthomonas maltophilia, oxacillin-resistant Staphylococcus spp. and Enterococcus spp. These species have demonstrated resistance to other carbapenems and to most of the newer cephalosporins. The results of this study, coupled with previously documented favorable qualities of biapenem, endorse further investigation of this broad-spectrum antibacterial agent for clinical use.
Collapse
Affiliation(s)
- H S Sader
- Department of Pathology, University of Iowa College of Medicine, Iowa City 52242
| | | |
Collapse
|
26
|
Murray PR, Jones RN, Allen SD, Erwin ME, Fuchs PC, Gerlach EH. Multilaboratory evaluation of the in vitro activity of 13 beta-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteria. Diagn Microbiol Infect Dis 1993; 16:191-203. [PMID: 8477573 DOI: 10.1016/0732-8893(93)90110-s] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The in vitro activity of 13 beta-lactam antibiotics against 1474 recent clinical isolates was evaluated in a multilaboratory study. The most active antibiotic tested in this study was imipenem (98.5% of the strains were susceptible), followed by ticarcillin-clavulanate (91.4%), cefoperazone (90.0%), ceftazidime (87.9%), cefotaxime (87.7%), ceftriaxone (87.0%), ceftizoxime (86.3%), cefotetan (78.5%), ampicillin-sulbactam (77.9%), cefoxitin (73.5%), cefuroxime (70.9%), cefonicid (64.5%), and cefazolin (57.9%).
Collapse
|
27
|
Brighty KE, Kohlbrenner W, McGuirk PR. Chapter 15. Recent Developments in Antibacterial Resistance Mechanisms. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 1993. [DOI: 10.1016/s0065-7743(08)60885-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/09/2023]
|
28
|
D'Amato C, Noto P, Bordi E, Falco C, Tocci G, Visco G. Imipenem-cilastatin for the treatment of bacterial complications in the immunocompromised host. Curr Ther Res Clin Exp 1992. [DOI: 10.1016/s0011-393x(05)80519-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
29
|
Leung JW, Chan CY, Lai CW, Ko TC, Cheng AF, French GL. Effect of biliary obstruction on the hepatic excretion of imipenem-cilastatin. Antimicrob Agents Chemother 1992; 36:2057-60. [PMID: 1416901 PMCID: PMC192439 DOI: 10.1128/aac.36.9.2057] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
The biliary excretion of imipenem-cilastatin studied by endoscopic cannulation of the common bile duct in patients with complete obstruction and in a group without obstruction showed that despite a 24-h prophylaxis, the bile obtained from patients with obstruction immediately after cannulation contained neither imipenem nor cilastatin, while there were 2 and 5% of peak concentrations in serum for imipenem and cilastatin, respectively, in the bile from patients without obstruction. Biliary excretion of both compounds increased rapidly after decompression, reaching a maximum of 15% of peak levels in serum within 2 h. Twenty-four hours after drainage, the biliary excretion of the drugs further improved. We conclude that since biliary obstruction impairs excretion of antibiotics, drainage is necessary for the control of sepsis in obstructed cholangitis.
Collapse
Affiliation(s)
- J W Leung
- Department of Medicine, Chinese University of Hong Kong, Shatin, New Territories
| | | | | | | | | | | |
Collapse
|
30
|
Boyce JM, Opal SM, Potter-Bynoe G, LaForge RG, Zervos MJ, Furtado G, Victor G, Medeiros AA. Emergence and nosocomial transmission of ampicillin-resistant enterococci. Antimicrob Agents Chemother 1992; 36:1032-9. [PMID: 1510390 PMCID: PMC188831 DOI: 10.1128/aac.36.5.1032] [Citation(s) in RCA: 80] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Between 1986 and 1988, the incidence of ampicillin-resistant enterococci increased sevenfold at a university-affiliated hospital. Forty-three patients acquired nosocomial infections with ampicillin-resistant enterococci, most of which were also resistant to mezlocillin, piperacillin, and imipenem. An analysis of plasmid and chromosomal DNAs of isolates revealed that the increase was due to an epidemic of 19 nosocomial infections that yielded closely related strains of Enterococcus faecium and to a significant increase in the incidence of nonepidemic, largely unrelated strains of ampicillin-resistant enterococci. The nonepidemic strains were identified as E. faecium, E. raffinosus, E. durans, and E. gallinarum. A logistic regression analysis revealed that patients with nonepidemic resistant strains were 16 times more likely than controls to have received preceding therapy with imipenem. In our institution, the increase in the incidence of ampicillin-resistant enterococci appears to be due to the selection of various strains of resistant enterococci by the use of imipenem and to the nosocomial transmission of E. faecium and E. raffinosus.
Collapse
Affiliation(s)
- J M Boyce
- Department of Medicine, Miriam Hospital, Providence, Rhode Island 02906
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Susceptibility of Aerobic and Facultative Anaerobic Organisms to Imipenem. Clin Drug Investig 1992. [DOI: 10.1007/bf03258398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Jones RN. Antimicrobial activity of Ro 41-1879, a new catechol cephalosporin. J Chemother 1991; 3:339-42. [PMID: 1819614 DOI: 10.1080/1120009x.1991.11739116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The antimicrobial activity and spectrum of Ro 41-1879, a new 7'-catechol substituted cephalosporin, was assessed in a broth microdilution system against 312 clinical isolates. Ro 41-1879 demonstrated a slightly superior spectrum of activity (2- to 32-fold) compared to ceftazidime against Gram-positive cocci, Pseudomonas spp. and Xanthomonas maltophilia. Enterobacteriaceae strains were more susceptible (97% versus 96%) to ceftazidime at less than or equal to 16 micrograms/ml. These results represent a preliminary potency/spectrum analysis for Ro 41-1879 since the screening studies were performed with an in vitro system unlikely to detect the potency contributed by active drug transport (tonB system) into bacterial cells. This new class of cephalosporins shows some therapeutic promise.
Collapse
Affiliation(s)
- R N Jones
- Clinical Microbiology Institute, Inc., Tualatin, Oregon
| |
Collapse
|
33
|
Abstract
Imipenem is the first of a new class of beta-lactam antibiotics, the carbapenems, to be released for clinical use. It has the broadest antibacterial activity of all antibiotics available for systemic use in humans. It is active against streptococci, methicillin-sensitive staphylococci, Neisseria, Haemophilus, anaerobes, and the common aerobic gram-negative nosocomial pathogens including Pseudomonas. Resistance to imipenem may emerge during treatment of P. aeruginosa infections, as has occurred with other beta-lactam agents; P. maltophilia and P. cepacia are typically resistant to it. Like the penicillins, imipenem has inhibitory activity against enterococci. Daily doses may range from 500 mg to 1 g, every 6 to 8 hours, in patients with normal renal function. The principal toxic effects have been nausea and vomiting, which occur during intravenous infusion, and seizures, which develop in 1 to 3% of treated patients and are likely to occur in the setting of renal insufficiency and underlying disease of the central nervous system. Imipenem should be considered for treatment of mixed bacterial infections and treatment of resistant aerobic gram-negative bacteria that are not susceptible to other beta-lactam agents. In addition to provoking unnecessary toxicity, indiscriminate use of this agent will promote dissemination of resistance against it.
Collapse
Affiliation(s)
- W C Hellinger
- Division of Infectious Diseases and Internal Medicine, Mayo Clinic Jacksonville, Florida
| | | |
Collapse
|
34
|
García-Rodríguez JA, García Sánchez JE, Muñoz Bellido JL, García Sánchez E, García García MI. In-vitro activity of meropenem, a new carbapenem, against imipenem-resistant Pseudomonas aeruginosa and Xanthomonas maltophilia. J Chemother 1991; 3:143-6. [PMID: 1919651 DOI: 10.1080/1120009x.1991.11739081] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The activity of meropenem, a new carbapenem, as well as imipenem, ceftazidime, aztreonam, tobramycin, amikacin and ciprofloxacin against 18 strains of Xanthomonas maltophilia and 23 strains of Pseudomonas aeruginosa resistant to imipenem was tested. All strains of X. maltophilia were resistant to both penems. Ceftazidime, tobramycin and ciprofloxacin were the most active antimicrobial agents against this specie. 17% of imipenem-resistant strains of P. aeruginosa were sensitive to meropenem. Ciprofloxacin, amikacin and aztreonam were the most effective agents against these strains.
Collapse
|
35
|
Erwin ME, Jones RN, Barrett MS, Briggs BM, Johnson DM. In vitro evaluation of GR69153, a novel catechol-substituted cephalosporin. Antimicrob Agents Chemother 1991; 35:929-37. [PMID: 1854174 PMCID: PMC245131 DOI: 10.1128/aac.35.5.929] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
GR69153 is a C-7 catechol cephalosporin with a broad spectrum of activity against members of the family Enterobacteriaceae (MICs for 50% of strains tested [MIC50s], 0.008 to 0.5 micrograms/ml), Staphylococcus aureus (MIC50, 4 micrograms/ml), Pseudomonas aeruginosa (MIC50, 0.25 micrograms/ml), Haemophilus influenzae (MIC50, 0.03 micrograms/ml), Neisseria gonorrhoeae (MIC50, 0.03 micrograms/ml), and Acinetobacter spp. (MIC50, 2 micrograms/ml). Potent GR69153 activity was also demonstrated against Moraxella catarrhalis, pneumococci, beta-hemolytic streptococci, gram-positive anaerobes, and most species of coagulase-negative staphylococci. The activity of GR69153 was generally two- to fourfold greater than that of ceftazidime. Resistance level GR69153 MICs for 90% of strains tested (greater than or equal to 32 micrograms/ml) were found most often among Citrobacter freundii, Enterobacter spp. and Morganella morganii strains. GR69153 did not significantly inhibit enterococci, Xanthomonas maltophilia, the Bacteroides fragilis group, Corynebacterium jeikeium, or Listeria monocytogenes. GR69153 was bactericidal and was generally beta-lactamase stable, and MICs were only slightly increased by high inoculum concentrations. Activity was enhanced in an iron-deficient medium, and a modest MIC difference attributed to iron availability was noted between standard agar and broth test results. GR69153 was confirmed to be a potent, catechol-substituted cephalosporin with a spectrum slightly wider than that of ceftazidime, but it was less active than cefpirome or imipenem against some gram-positive pathogens and anaerobes.
Collapse
Affiliation(s)
- M E Erwin
- Department of Pathology, University of Iowa College of Medicine, Iowa City 52242
| | | | | | | | | |
Collapse
|
36
|
In Vitro Activity of FCE-22101 and Other Antimicrobials Against Anaerobic Bacteria. Clin Drug Investig 1991. [DOI: 10.1007/bf03259549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
37
|
Affiliation(s)
- T T Yoshikawa
- Office of Geriatrics and Extended Care, Department of Veterans Affairs, Washington, D.C. 20420
| |
Collapse
|
38
|
Solomkin JS, Dellinger EP, Christou NV, Busuttil RW. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg 1990; 212:581-91. [PMID: 2241313 PMCID: PMC1358185 DOI: 10.1097/00000658-199011000-00004] [Citation(s) in RCA: 157] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
We designed a multicenter study to compare tobramycin/clindamycin to imipenem/cilastatin for intra-abdominal infections. We included the Acute Physiology and Chronic Health Evaluation (APACHE II) index of severity and excluded patients without established infection. Two hundred ninety patients were enrolled, of whom 162 were evaluable. Using logistic regression to analyze both outcome at the abdominal site of infection and outcome as mortality, we found a significant correlation for both with APACHE II score (p less than 0.0001 for both). Next we analyzed the residual effect of treatment assignment and found a significant improvement in outcome for imipenem/cilastatin-treated patients (p = 0.043). The differences in outcome were explained by a higher failure rate for patients with gram-negative organisms for tobramycin/clindamycin-treated patients (p = 0.018). This was reflected in a significantly higher incidence of fasciitis requiring reoperation and prosthetic fascial replacement. Maximum peak tobramycin levels were analyzed for 63 tobramycin/clindamycin patients harboring gram-negative organisms. For failures the maximum peak was 6.4 +/- 1.9 micrograms/mL, and time to maximum peak was 4.6 +/- 5.2 days. For successes the maximum peak was 6.1 +/- 1.7 micrograms/mL, occurring at 3.8 +/- 2.6 days. This study supports inclusion of severity scoring in statistical analyses of outcome results and supports the notion that imipenem/cilastatin therapy improves outcome at the intra-abdominal site of infection as compared to a conventionally prescribed amino-glycoside-based regimen.
Collapse
Affiliation(s)
- J S Solomkin
- Department of Surgery, University of Cincinnati College of Medicine, Ohio 45267
| | | | | | | |
Collapse
|
39
|
May T, Rousselot J, Mory F, Canton P. Infection neonatale a Campylobacter fetus subsp fetus. A propos d'une observation traitee par imipenem. Med Mal Infect 1990. [DOI: 10.1016/s0399-077x(05)81138-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
40
|
Elting LS, Khardori N, Bodey GP, Fainstein V. Nosocomial Infection Caused by Xanthomonas maltophilia: A Case-Control Study of Predisposing Factors. Infect Control Hosp Epidemiol 1990. [DOI: 10.2307/30145475] [Citation(s) in RCA: 79] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
41
|
Jones RN, Pfaller MA, Fuchs PC, Aldridge K, Allen SD, Gerlach E. Piperacillin/tazobactam (YTR 830) combination. Diagn Microbiol Infect Dis 1989. [DOI: 10.1016/0732-8893(89)90083-7] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
42
|
Sumita Y, Inoue M, Mitsuhashi S. In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338. Eur J Clin Microbiol Infect Dis 1989; 8:908-16. [PMID: 2512140 DOI: 10.1007/bf01963782] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The in vitro activity of the new carbapenem SM-7338 was tested in comparison with imipenem, ceftazidime, cefotaxime, flomoxef, cefuzonam and cefmetazole against 2850 clinical bacterial isolates. SM-7338 showed good activity against a broad spectrum of gram-positive and gram-negative bacteria. SM-7338 was very active against gram-negative bacteria, inhibiting all Enterobacteriaceae, except 25% of Serratia marcescens isolates, at a concentration of 0.78 mg/l. SM-7338 inhibited the majority of Pseudomonas spp. at concentrations of less than or equal to 3.13 mg/l, its activity being twofold higher than that of imipenem. However, the activity of SM-7338 against gram-positive cocci was about one-fourth that of imipenem. Against anaerobes, SM-7338 also had the best activity of the beta-lactams tested. The compound was inactive against methicillin-resistant staphylococci, Enterococcus faecium, Xanthomonas maltophilia and Flavobacterium spp., as were the other beta-lactams. SM-7338 was quite stable in the presence of various types of beta-lactamase, but was hydrolyzed by Xanthomonas maltophilia beta-lactamase, as was imipenem. This high degree of stability was responsible for the potent activity of SM-7388 against beta-lactamase-producing species such as Enterobacter cloacae, Citrobacter freundii and Proteus vulgaris. SM-7338 also showed bactericidal activity against clinical isolates at the MIC or at concentrations slightly above the MIC.
Collapse
|
43
|
|
44
|
Jones RN, Gardiner RV. Stability of SM-7338, a new carbapenem in mediums recommended for the susceptibility testing of anaerobic bacteria and gonococci. Diagn Microbiol Infect Dis 1989; 12:271-3. [PMID: 2507217 DOI: 10.1016/0732-8893(89)90027-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The stability of SM-7338 was compared to that of imipenem in media used for susceptibility testing anaerobic bacteria and Neisseria gonorrhoeae. SM-7338 was more stable in all media than imipenem. For tests with anaerobic bacteria, the broth-disk elution (in thioglycolate) and other methods recommended by the National Committee for Clinical Laboratory Standards can be accurately used for SM-7338. However, the cysteine content of IsoVitaleX (25.9 g/L) supplement inactivates SM-7338 (20-fold reduction) in gonococcal susceptibility test systems with GC agar base. A cysteine-free supplement would be advised for tests with the carbapenems and clavulanic acid. The SM-7338 disk diffusion test (10 micrograms) results were not significantly influenced by the inactivating substances in the media.
Collapse
Affiliation(s)
- R N Jones
- Clinical Microbiology Institute, Tualatin, Oregon 97062
| | | |
Collapse
|
45
|
Jones RN, Barry AL. In vitro activity of Ro 23-9424, ceftazidime, and eight other newer beta-lactams against 100 gram-positive blood culture isolates. Diagn Microbiol Infect Dis 1989; 12:143-7. [PMID: 2666014 DOI: 10.1016/0732-8893(89)90005-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
One hundred Gram-positive bacteremia organisms from five important genus groups were tested against 10 newer beta-lactams. Ceftazidime was significantly less active (50% of strains at less than or equal to 8 micrograms/ml) compared to other cephalosporins. The penems (FCE-22101 and HRE-664) and imipenem were each superior to the cephalosporins with 92-93% inhibition of strains. A novel fused co-drug of fleroxacin and desacetyl-cefotaxime, Ro 23-9424, was 100% effective against these Gram-positive pathogens at less than or equal to 8 micrograms/ml. Several of these compounds should receive consideration for clinical trials for empiric therapy among neutropenic patient infections where Gram-positive pathogens may be more prevalent.
Collapse
Affiliation(s)
- R N Jones
- Clinical Microbiology Institute, Tualatin, Oregon
| | | |
Collapse
|
46
|
Marchini E, Belgrano G, Calvi P, Michelotti P, Cantagallo E, Pescatore D. Un Antibiotico Beta-Lattamico Della Classe Delle Tienamicine Nel Trattamento Delle Uti Complicate. Urologia 1989. [DOI: 10.1177/039156038905600115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
47
|
Abstract
Successful management of anaerobic infection first requires an accurate diagnosis. Cytologic examination of wound exudates and inspection for characteristic clinical clues greatly facilitates an accurate initial diagnosis of anaerobic infection. Knowledge of antimicrobial activity against specific anaerobic pathogens is essential, since antibiotic susceptibility information is not routinely available. Whenever possible, antimicrobial and surgical therapy should be combined in managing anaerobic infections. Chloramphenicol, clindamycin, and metronidazole provide the most consistently reliable activity against pathogenic anaerobes, including Bacteroides. Penicillins are also generally effective, except for treatment of infections caused by penicillinase-producing strains of Bacteroides. Cephalosporins are not considered drugs of choice for anaerobic infections, although cefoxitin may in some instances be useful as monotherapy of mixed infections containing obligate anaerobes and coliform bacteria. Aminoglycosides and sulfonamides are ineffective and should be avoided for treatment of anaerobic infection.
Collapse
Affiliation(s)
- S W Dow
- Department of Pathology, Colorado State University College of Veterinary Medicine and Biomedical Sciences, Fort Collins
| |
Collapse
|
48
|
Affiliation(s)
- G May
- Vanderbilt University Medical Center, Nashville, TN 37232
| |
Collapse
|
49
|
Knöller J, König W, Schönfeld W, Bremm KD, Köller M. Application of high-performance liquid chromatography of some antibiotics in clinical microbiology. JOURNAL OF CHROMATOGRAPHY 1988; 427:257-67. [PMID: 3165979 DOI: 10.1016/0378-4347(88)80128-2] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
During recent years high-performance liquid chromatography has become an excellent tool for the determination of antibiotics in biological fluids. Compared with biological assays, the major benefits of this method are specificity and rapidity. In particular, the determination of biologically inactive metabolites emphasizes that this technique plays an outstanding role for the analysis of antibiotics. This paper describes how the method can be used in the analysis of several antibiotics and demonstrates the efficacy of this method for clinical microbiology. Methods for the determination in biological fluids of acylaminopenicillins (azlocillin, mezlocillin, piperacillin and aspoxicillin), quinolones (ciprofloxacine, norfloxacine and ofloxacine), a penem (imipenem) and a cephalosporin (cefixime) are summarized. Furthermore, their application to in vitro studies and their trial in clinical studies are described.
Collapse
Affiliation(s)
- J Knöller
- Lehrstuhl für Medizinische Mikrobiologie und Immunologie, Ruhr Universität, Bochum, F.R.G
| | | | | | | | | |
Collapse
|
50
|
Bumgardner GL, Simmons RL. Newer cephalosporins: lessons to be learned from clinical trials in intraabdominal infections. Am J Surg 1988; 155:5-10. [PMID: 3287968 DOI: 10.1016/s0002-9610(88)80205-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Recent clinical trials testing the efficacy of newer cephalosporins in intraabdominal infections lack a number of the study design criteria proposed by Solomkin et al. Nevertheless, these trials all support the use of these newer cephalosporins in the treatment of intraabdominal infections. These newer agents demonstrate increased in vitro antimicrobial activity against potential aerobic pathogens, which suggests that they may be used in combination with an antianaerobic drug in the treatment of intraabdominal infections. Therefore, agents including cefotaxime, cefoperazone, ceftazidime, cefuroxime, ceftriaxone, and aztreonam may be chosen in place of the standard aminoglycoside. Previous studies have demonstrated the necessity of both aerobic and anaerobic coverage in empiric therapy of intraabdominal infections. Cefotetan, ceftizoxime, cefoxitin, moxalactam, mezlocillin, and piperacillin all have in vitro activity against aerobes and anaerobes (including B. fragilis), thus, these agents have a potential as monotherapy for acute intraabdominal infections in otherwise healthy patients. Directed combination chemotherapy or perhaps imipenem alone is recommended for persistent peritonitis and intraabdominal infections in immunocompromised hosts.
Collapse
Affiliation(s)
- G L Bumgardner
- Department of Surgery, University of Minnesota School of Medicine, Minneapolis
| | | |
Collapse
|